Swiss authorities grant product approval for Intercell's IXIARO
Vaccine to help prevent Japanese Encephalitis now available in Switzerland
The decision by the Swiss authorities represents another important milestone for the licensure process initiated for selected attractive market segments. Intercell's vaccine, which helps to prevent Japanese Encephalitis, has already been approved and launched in the USA, Europe, Canada and Australia.
"The Swissmedic approval is great news and another important step in the product's global reach", states Thomas Lingelbach, Chief Operating Officer of Intercell.
IXIARO® is a modern purified, inactivated vaccine for active immunization of adults against infections caused by the Japanese Encephalitis Virus. IXIARO®is manufactured at Intercell's proprietary manufacturing facility in Scotland using tissue culture rather than live organisms.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.